MODDERN Cures Solution Modernizing Our Drug and Diagnostics Evaluation and Regulatory Networks Marc Boutin Executive Vice ...
The mission of the National Health Council is to provide a united voice for people with chronic diseases and disabilities....
Despite many medical breakthroughs, significant  unmet need  remains for millions of people suffering from chronic conditi...
© National Health Council  ALZHEIMER’S DISEASE CASE STUDY 100 + YEARS CLINICAL TRIALS 1990s Testing of early drugs to trea...
© National Health Council  ALS CASE STUDY 140 + YEARS CLINICAL TRIALS 1993 Trials on Riluzole begin 2009 FDA approval of S...
© National Health Council  PKD CASE STUDY CLINICAL TRIALS 2000 CRISP Disease  progression and TKV 2011 Tolvaptan Phase III...
Addressing Unmet Need  <ul><li>Moses H, Dorsey E, Matheson D, Thier S (2005). &quot;Financial anatomy of biomedical resear...
BARRIER #1:  Drug compounds not developed  because of insufficient legal protection © National Health Council
Why Patents Don’t Always Work  <ul><li>Compound is reasonably likely to succeed </li></ul><ul><li>A discovery was publicly...
Stages of Research and Development © National Health Council  Drug Discovery Preclinical Phase Clinical  Trials FDA  Revie...
Lost Opportunities © National Health Council  Company Product Description Development stage Disease Abbott ABT-491 Elastas...
<ul><li>Create a new class of drugs called dormant therapies </li></ul><ul><ul><li>Address unmet need </li></ul></ul><ul><...
© National Health Council
BARRIER #2: Lack of alignment between  market incentives and  personalized medicine © National Health Council
 
<ul><li>Use data protection to encourage  </li></ul><ul><li>co-developed and companion diagnostics </li></ul><ul><li>Advan...
BARRIER #3: Delayed access to FDA-approved  diagnostic tools © National Health Council
© National Health Council  PathVysion: HER-2 DNA Test to Identify Candidates for Herceptin Breast Cancer Therapy <ul><li>D...
<ul><li>Allow diagnostic manufacturers to apply for temporary national code until permanent code can be assigned </li></ul...
BARRIER #4: Outdated reimbursement system for diagnostics © National Health Council
 
<ul><li>Identify key factors to be considered when determining payment amount for new diagnostic tests </li></ul><ul><ul><...
Estimated Outlay and Revenue Effects of  MODDERN Cures Solution (Outlay Increases are positive number) © National Health C...
 
<ul><li>Ensures that science, not the law, drives the development of new therapies </li></ul><ul><li>Promotes targeted the...
Marc Boutin Executive Vice President & COO National Health Council [email_address]
Upcoming SlideShare
Loading in...5
×

MODDERN Cures Solution

754

Published on

The MODDERN Cures Solution updates the regulatory system by removing barriers to invention and providing greater predictability in the search for answers to our nation’s unmet medical needs. It’s in everyone’s interest to push for a MODDERN regulatory system that encourages scientific inquiry, rewards ingenuity, and safely speeds modern miracles into everyday diagnostics and treatments that improve patient outcomes.

Published in: Health & Medicine, Business
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
754
On Slideshare
0
From Embeds
0
Number of Embeds
0
Actions
Shares
0
Downloads
0
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

MODDERN Cures Solution

  1. 1. MODDERN Cures Solution Modernizing Our Drug and Diagnostics Evaluation and Regulatory Networks Marc Boutin Executive Vice President & COO National Health Council May 2011
  2. 2. The mission of the National Health Council is to provide a united voice for people with chronic diseases and disabilities. © National Health Council
  3. 3. Despite many medical breakthroughs, significant unmet need remains for millions of people suffering from chronic conditions. © National Health Council
  4. 4. © National Health Council ALZHEIMER’S DISEASE CASE STUDY 100 + YEARS CLINICAL TRIALS 1990s Testing of early drugs to treat symptoms 1990s-Present Tests of diagnostics to identify plaque in brain TRANSLATIONAL RESEARCH 1976-Early ‘90s R&D of first drugs for symptoms 1976-Present Search for drugs to treat or prevent disease 1980s-2001 Research Dx test to detect amyloid BASIC RESEARCH 1906 First Identified 1976 High prevalence acknowledged FDA EVALUATION/APPROVAL 1990s-Present Total of 4 drugs approved to treat symptoms Still waiting for diagnostic tools to accurately identify patients and treatments to prevent, slow, or arrest disease.
  5. 5. © National Health Council ALS CASE STUDY 140 + YEARS CLINICAL TRIALS 1993 Trials on Riluzole begin 2009 FDA approval of SOD1 antisense and stem cell trials TRANSLATIONAL RESEARCH 1950s-Present Research conducted to identify treatments 1950s Nerve growth factor identified 1990 Growth factor CNTF found to increase survival of motor neurons BASIC RESEARCH 1869 First identified 1939 Lou Gehrig diagnosed 1993 SOD1 gene mutation found in familial ALS 2000 NINDS issues first RFA for ALS research FDA EVALUATION/ APPROVAL 1996-Present Riluzole approved by the FDA It extends life approximately 3 months in some patients No other approved treatment available Still waiting for a cure, diagnostic tools, and treatments that slow or stop the progression of ALS. Meanwhile, the average patient dies within 2-5 years of diagnosis.
  6. 6. © National Health Council PKD CASE STUDY CLINICAL TRIALS 2000 CRISP Disease progression and TKV 2011 Tolvaptan Phase III trial Additional Trials: somatostatin, sirolimus & bosutinib <ul><li>TRANSLATIONAL RESEARCH </li></ul><ul><li>1995 – Present: </li></ul><ul><li>Identification of disease pathways </li></ul><ul><li>cAMP </li></ul><ul><li>Vasopressin </li></ul><ul><li>mTOR </li></ul><ul><li>AKT </li></ul>BASIC RESEARCH 1757 First identified 1957 First demographic study 1994 PKD1 gene identified 1996 PKD2 gene identified FDA Evaluation/ Approval 2010 PKD Outcomes Consortium: Analyze patient registry data for validation of TKV as a clinical endpoint for CT’s No therapies have been approved to treat PKD. Still waiting for treatments to slow or stop progression. Meanwhile, 50% of PKD patients will go into ESRD by age 60. Dialysis and transplantation remain the only options available. 250 + YEARS
  7. 7. Addressing Unmet Need <ul><li>Moses H, Dorsey E, Matheson D, Thier S (2005). &quot;Financial anatomy of biomedical research.&quot;. JAMA 294 (11): 1333–42. doi:10.1001/jama.294.11.1333. PMID 16174691 </li></ul><ul><li>Dorsey ER, Thompson JP, Carrasco M, de Roulet J, Vitticore P, et al. 2009 Financing of U.S. Biomedical Research and New Drug Approvals across Therapeutic Areas. PLoS ONE 4(9): e7015. doi:10.1371/journal.pone.0007015 </li></ul>
  8. 8. BARRIER #1: Drug compounds not developed because of insufficient legal protection © National Health Council
  9. 9. Why Patents Don’t Always Work <ul><li>Compound is reasonably likely to succeed </li></ul><ul><li>A discovery was publicly disclosed before a patent application was filed. </li></ul><ul><li>A new treatment was patented, but not approved by the FDA. The patent has since expired. </li></ul><ul><li>A patent application was filed but withdrawn prior to approval. </li></ul>© National Health Council
  10. 10. Stages of Research and Development © National Health Council Drug Discovery Preclinical Phase Clinical Trials FDA Review 5,000 to 10,000 Compounds  250 Compounds  5 Compounds Clinical Phases I II III  One FDA-Approved Drug 3 to 6 Years 6 to 7 Years 0.5 to 2 Years
  11. 11. Lost Opportunities © National Health Council Company Product Description Development stage Disease Abbott ABT-491 Elastase inhibitor Clinical Trials Asthma Novartis Recombinant AT-1 Alpha1-Antitripsin Phase II Emphysema Dupont CMP-777 Proteinase inhibitor Phase I/II CF, Emphysema Cortech/United Ther CE-1037 HNE inhibitor Phase II CF, Emphysema, ARDS Cortech/Ono CE-2000 series HNE inhibitor Pre-clinical CF, Emphysema Dyax EPI-HNE-4 HNE inhibitor Clinical Bronchitis, CF, Emphysema Amgen SLP-1 Recombinant inhibitor Pre-clinical Asthma Biogenidec BG-12 Fumarate derivative Phase III MS
  12. 12. <ul><li>Create a new class of drugs called dormant therapies </li></ul><ul><ul><li>Address unmet need </li></ul></ul><ul><ul><ul><li>Where there is no available treatment or </li></ul></ul></ul><ul><ul><ul><li>Where the new treatment </li></ul></ul></ul><ul><ul><ul><ul><li>Improves outcomes or </li></ul></ul></ul></ul><ul><ul><ul><ul><li>Reduces risk </li></ul></ul></ul></ul><ul><ul><li>Have insufficient patent protection </li></ul></ul><ul><li>Emphasize therapies to stop or slow disease progression </li></ul>MODDERN Cures Solution #1 © National Health Council
  13. 13. © National Health Council
  14. 14. BARRIER #2: Lack of alignment between market incentives and personalized medicine © National Health Council
  15. 16. <ul><li>Use data protection to encourage </li></ul><ul><li>co-developed and companion diagnostics </li></ul><ul><li>Advance personalized medicine: </li></ul><ul><ul><li>Get the right treatment to the right patient </li></ul></ul><ul><ul><li>at the right time </li></ul></ul>MODDERN Cures Solution #2 © National Health Council
  16. 17. BARRIER #3: Delayed access to FDA-approved diagnostic tools © National Health Council
  17. 18. © National Health Council PathVysion: HER-2 DNA Test to Identify Candidates for Herceptin Breast Cancer Therapy <ul><li>DIAGNOSTIC DEVELOPMENT </li></ul><ul><li>1994 Initial Development Begins </li></ul>PRE-VALIDATION VALIDATION <ul><li>REGULATORY SUBMISSION </li></ul><ul><li>1999 FDA Approval </li></ul><ul><li>2000-04 CMS </li></ul><ul><li>Reimbursement Code </li></ul><ul><li>2005 Coding Implemented </li></ul>BIOMARKER DISCOVERY PRODUCT LAUNCH 11 YEARS
  18. 19. <ul><li>Allow diagnostic manufacturers to apply for temporary national code until permanent code can be assigned </li></ul><ul><li>Temporary assignments should occur quarterly throughout the year </li></ul>MODDERN Cures Solution #3 © National Health Council
  19. 20. BARRIER #4: Outdated reimbursement system for diagnostics © National Health Council
  20. 22. <ul><li>Identify key factors to be considered when determining payment amount for new diagnostic tests </li></ul><ul><ul><li>Impact on Care </li></ul></ul><ul><ul><li>Laboratory Charges </li></ul></ul><ul><ul><li>Private Insurance Rates </li></ul></ul><ul><li>Establish independent advisory panel comprised of diagnostic experts, including patients </li></ul>MODDERN Cures Solution #4 © National Health Council
  21. 23. Estimated Outlay and Revenue Effects of MODDERN Cures Solution (Outlay Increases are positive number) © National Health Council Provision 5-Year Cost or Revenue Loss 10-Year Cost or Revenue Loss Accelerate the Release of Guidelines – – Improve the Coding and Reimbursement System $5 million $10 million Companion Diagnostics for Existing Drugs/Co-developed Companion Diagnostics negligible $10 million Dormant Therapies – – Total Cost $5 million $20 million
  22. 25. <ul><li>Ensures that science, not the law, drives the development of new therapies </li></ul><ul><li>Promotes targeted therapies </li></ul><ul><li>Guarantees immediate access to FDA approved diagnostic tests </li></ul><ul><li>Rationalizes the reimbursement system </li></ul>MODDERN Cures Solution © National Health Council
  23. 26. Marc Boutin Executive Vice President & COO National Health Council [email_address]

×